Posts

Broad Institute launches Center for Therapeutic Genetics for rare diseases

on

Recent News: ARPA-H Awards Up to $160M for Custom Genetic Medicines

on

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

China gene editing startup YolTech raises $70M to move CRISPR therapies forward

on

Profluent and Eli Lilly Announce $2.25 Billion Partnership for AI-Designed Genetic Medicines

on

Intellia Therapeutics Advances In Vivo CRISPR Therapy Lonvo-z to FDA After Positive Phase 3 HAELO Trial Results

on

FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN

on

Eli Lilly Partners with Seamless Therapeutics on Up to $1.12B Recombinase Gene Editing Deal for Hearing Loss

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies

on

FDA Unveils 'Plausible Mechanism Pathway' to Accelerate Personalized Therapies, Inspired by Baby KJ

on

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

on

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

on

Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset

on

Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio

on

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

on

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

on

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

on